Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

Recruiting Phase 2 Interventional Study
Advanced Rectal Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
121 (estimated)
Sponsor
Zhen-Hai Lu · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy. For this reason, the concept of reducing the dose of postoperative chemotherapy or directly moving forward the full amount of postoperative chemotherapy was proposed, which is called total neoadjuvant therapy (TNT). However, TNT also i…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Pathological confirmed rectal adenocarcinoma. Clinical stage T3-4 or T any N1.With or without MRF positivity, with or without EMVI positivity, R0 resection is estimated. No metastasis No signs of intestinal obstruction; or intestinal obstruction has been relieved after proxim…
Contacts

Zhenhai Lu, Prof

+862087343584

luzhh@sysucc.org.cn

CONTACT

Jianhong Peng, M.D

+862087343584

pengjh@sysucc.org.cn

CONTACT